https://assets.capyfin.com/instruments/678fdc13234e27009c5d583e.png avatar
Danaher
🇺🇸 NYSE:DHR
View Company
OverviewEarningsDividends
•
Dec 31, 2023

Danaher Q4 2023 Earnings Report

Danaher's fourth quarter results were announced, revealing a year-over-year revenue decrease of 10.0% to $6.4 billion and net earnings of $1.1 billion.

Key Takeaways

Danaher reported fourth quarter 2023 results with revenues decreasing 10.0% year-over-year to $6.4 billion. Net earnings were $1.1 billion, or $1.50 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.09. The company exceeded margin and cash flow expectations despite a dynamic market environment, with respiratory revenue at Cepheid leading the way.

Net earnings were $1.1 billion, or $1.50 per diluted common share.

Non-GAAP adjusted diluted net earnings per common share were $2.09.

Revenues decreased 10.0% year-over-year to $6.4 billion.

Non-GAAP core revenue decreased 11.5%, including a 4.5% non-GAAP base business core revenue decline.

Total Revenue
$6.41B
Previous year: $8.37B
-23.5%
EPS
$2.09
Previous year: $2.87
-27.2%
Core Sales Growth
-11.5%
Previous year: 7.5%
-253.3%
Gross Profit
$1.62B
Previous year: $4.94B
-67.1%
Cash and Equivalents
$5.86B
Previous year: $6B
-2.2%
Free Cash Flow
$1.2B
Previous year: $2.21B
-45.8%
Total Assets
$84.5B
Previous year: $84.4B
+0.2%

Danaher

Danaher

Danaher Revenue by Segment

Forward Guidance

For the first quarter 2024, the Company anticipates that non-GAAP core revenue will be down high-single digits year-over-year. For full year 2024, the Company anticipates that non-GAAP core revenue will be down low-single digits year-over-year.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Danaher